We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+4.9%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$265M
AUM Growth
+$37.5M
(+17%)
Cap. Flow
+$34M
Cap. Flow
% of AUM
12.86%
Top 10 Holdings %
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DT Midstream
DTM
|
+$1.85M |
| 2 |
Delek US
DK
|
+$898K |
| 3 |
ScottsMiracle-Gro
SMG
|
+$843K |
| 4 |
Valero Energy
VLO
|
+$783K |
| 5 |
FMC
FMC
|
+$709K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COR
Coresite Realty Corporation
COR
|
+$1.67M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$601K |
| 3 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
+$551K |
| 4 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
+$448K |
| 5 |
Travere Therapeutics
TVTX
|
+$434K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 22.39% |
| 2 | Healthcare | 18.38% |
| 3 | Energy | 15.88% |
| 4 | Materials | 14.07% |
| 5 | Utilities | 13.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BRW
176
Saba Capital Income & Opportunities Fund
BRW
$336M
| $367K | 0.14% |
40,597
-2,501
| -6% | -$22.9K |
|
177
Capital Southwest
CSWC
$1.46B
| $367K | 0.14% |
14,519
-9,342
| -39% | -$250K |
|
178
Ascendis Pharma A/S
ASND
$16.6B
| $366K | 0.14% |
2,722
+1,141
| +72% | +$170K |
|
179
Vanda Pharmaceuticals
VNDA
$314M
| $366K | 0.14% |
23,335
-358
| -2% | -$6.24K |
|
|
ONC
180
BeOne Medicines Ltd
ONC
$33.8B
| $362K | 0.14% |
1,336
+8
| +0.6% | +$2.7K |
|
181
Kiniksa Pharmaceuticals
KNSA
$4.89B
| $353K | 0.13% |
30,021
+12
| +0% | +$147 |
|
182
Regeneron Pharmaceuticals
REGN
$69.9B
| $350K | 0.13% |
554
-307
| -36% | -$189K |
|
183
BioNTech
BNTX
$23B
| $346K | 0.13% |
1,344
-729
| -35% | -$200K |
|
184
Moderna
MRNA
$22.1B
| $341K | 0.13% |
1,342
-866
| -39% | -$253K |
|
185
Alnylam Pharmaceuticals
ALNY
$37.2B
| $340K | 0.13% |
2,003
-742
| -27% | -$138K |
|
|
TSVT
186
DELISTED
2seventy bio
TSVT
| $337K | 0.13% |
+13,134
| New | +$410K |
|
187
Gladstone Investment Corp
GAIN
$648M
| $336K | 0.13% |
19,668
-13,470
| -41% | -$215K |
|
188
Crescent Capital BDC
CCAP
$403M
| $328K | 0.12% |
18,653
+1,651
| +10% | +$31.7K |
|
189
Main Street Capital
MAIN
$5B
| $327K | 0.12% |
7,297
-3,346
| -31% | -$147K |
|
|
BCIC
190
BCP Investment Corp
BCIC
$88.1M
| $295K | 0.11% |
11,905
-2,154
| -15% | -$52.8K |
|
191
OFS Capital
OFS
$46M
| $285K | 0.11% |
26,142
-6,944
| -21% | -$76.3K |
|
192
Oxford Square Capital
OXSQ
$148M
| $282K | 0.11% |
69,162
-8,860
| -11% | -$36.9K |
|
|
FCRD
193
DELISTED
First Eagle Alternative Capital BDC, Inc. Common Stock
FCRD
| $276K | 0.1% |
61,721
-10,730
| -15% | -$49.9K |
|
194
Arcutis Biotherapeutics
ARQT
$3.48B
| $227K | 0.09% |
10,965
+3,661
| +50% | +$72.9K |
|
|
KZR
195
DELISTED
Kezar Life Sciences
KZR
| $222K | 0.08% |
+1,329
| New | +$150K |
|
196
Stoke Therapeutics
STOK
$1.83B
| $218K | 0.08% |
9,070
+3,568
| +65% | +$85.1K |
|
|
IMGO
197
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $215K | 0.08% |
+9,065
| New | +$210K |
|
198
Invesco Senior Loan ETF
BKLN
$6.97B
| $214K | 0.08% |
+9,683
| New | +$214K |
|
199
Arvinas
ARVN
$530M
| $205K | 0.08% |
2,494
-36
| -1% | -$2.93K |
|
|
ITOS
200
DELISTED
iTeos Therapeutics
ITOS
| $205K | 0.08% |
4,412
-3,319
| -43% | -$110K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q4 2021 Portfolio in Review
As of Q4 2021, Virtus ETF Advisers held 421 positions worth $265M, up 17% from $227M the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.
Virtus ETF Advisers deployed $34M of net new capital in Q4 2021, opening 24 new positions and adding to 206 existing holdings. Its largest new stake was Invivyd: 22,625 shares worth $164K.
By sector, the portfolio is most concentrated in Real Estate at 22% of assets, up from 20% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Travere Therapeutics, an estimated $434K trimmed.
- Virtus ETF Advisers's largest Q4 2021 buy was Invivyd: 22,625 shares worth $164K.
- Virtus ETF Advisers added most to DT Midstream in Q4 2021, an estimated $1.85M increase.
- Virtus ETF Advisers's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $434K.
- Virtus ETF Advisers fully exited Coresite Realty Corporation in Q4 2021, selling an estimated $1.67M.
- Virtus ETF Advisers's ten largest holdings make up 9.2% of its $265M portfolio in Q4 2021.
- Virtus ETF Advisers opened 24 new positions and closed 45 in Q4 2021.
- Virtus ETF Advisers's portfolio value rose 17% quarter-over-quarter to $265M.
Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.